Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma.

导出 OA

翻译打印收藏纠错

作者： Andrew M,Evens ^[1] ; Justin S,Brandt ^[2] ; Cody J,Peer ^[2] ; Tyler,Yin ^[3] ; Dale,Schaar ^[3] ; Faheem,Farooq ^[1] ; Brett,Mozarsky ^[1] ; William D,Figg ^[3] ; Elad,Sharon ^[3]

作者单位： Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. ^[1] Departments of Medicine and Maternal Fetal Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA. ^[2] Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA. ^[3] Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. ^[4]

主题词女(雌)性(Female);霍奇金病(Hodgkin Disease);人类(Humans);免疫因子类(Immunologic Factors);免疫疗法(Immunotherapy);妊娠(Pregnancy)

DOI 10.1002/ajh.26527

PMID 35285979

发布时间 2022-07-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交